SCHEMBL7126697

SCHEMBL7126697

COC(=O)c1ccc(C(=O)c2ccc(N)cc2)cc1C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
ALDH1A1 P00352 5/20 0.56
GAA P10253 4/20 0.56
HSD17B10 Q99714 4/20 0.56
MAPT P10636 3/20 0.56
HPGD P15428 2/20 0.56
GLA P06280 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
ATM Q13315 1/20 0.56
ABL1 P00519 1/20 0.46
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HTT P42858 1/20 0.45
CFTR P13569 2/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784000 0.89 KDM4E (0.56) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2884838 0.86 ALDH1A1 (0.47) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL27586077 0.85 TSHR (0.55) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL1403643 0.82 GAA (0.72) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL7908252 0.82 CA1 (0.57) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL8013838 0.81 POLB (0.59) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL13941280 0.81 POLB (0.58) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL8013837 0.81 POLB (0.58) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL29586986 0.81 POLB (0.58) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL7623605 0.80 GAA (0.70) KDM4EALDH1A1GAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM KDM4E 484/4885ALDH1A1 901/4885GAA 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.